Overview

To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

Status:
COMPLETED
Trial end date:
2023-12-07
Target enrollment:
Participant gender:
Summary
This was a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 Tincture in Chinese adult female subjects with AGA.
Phase:
PHASE2
Details
Lead Sponsor:
Suzhou Koshine Biomedica, Inc.